ABT-436
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ABT-436 is an orally active, highly selective vasopressin V 1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued. It reached phase II clinical trials prior to the discontinuation of its development.
ABT-436 is an orally active, highly selective vasopressin V 1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued. It reached phase II clinical trials prior to the discontinuation of its development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372014562 under CC BY-SA 4.0; modifications have been made.